Pharmacotherapy considerations in pregnant patients on hemodialysis

Abstract

AbstractPurposeSuccessful pregnancy rates on dialysis are increasing with the advent of intensive hemodialysis and advances in medical management.SummaryData support the use of intensive hemodialysis in pregnant women with end‐stage kidney disease (ESKD). This paper provides an overview of common pharmacotherapeutic changes in management when caring for a pregnant woman receiving intensive hemodialysis. Pregnant patients on peritoneal dialysis were excluded from this analysis due to insufficient data. Topics covered include those related to anemia (iron and erythropoietin stimulating agents), blood pressure agents, monitoring of phosphorus, as well as nutrition and anticoagulation.ConclusionWhen patients on hemodialysis become pregnant, medication adjustments are needed regarding antihypertensives, anemia management, and mineral‐bone disease management as many agents require dose adjustment, switching agents due to teratogenicity, or cessation due to fetal complications. There are minimal data in this population; however, successful and healthy infants have been delivered in this patient population with the medication changes discussed.